Robert Stewart is the CEO of Amneal Pharmaceuticals, a company focused on generic medications and pharmaceutical products. He holds a Bachelor’s degree in Pharmacy from the University of Southern California, bringing valuable knowledge from his educational background to the pharmaceutical...

Robert Stewart is the CEO of Amneal Pharmaceuticals, a company focused on generic medications and pharmaceutical products. He holds a Bachelor’s degree in Pharmacy from the University of Southern California, bringing valuable knowledge from his educational background to the pharmaceutical industry. Since his appointment as CEO, he has overseen significant changes in the company structure including the welcoming of new board members that resulted from strategic partnerships. Stewart's leadership plays a crucial role in aligning company goals with the interests of shareholders, striving for improved performance metrics in revenue and EBITDA. His compensation structure reflects the company's accountability, incentivizing performance with bonuses tied to financial goals. In 2019, he earned a total of $950,000, which included a salary, bonus, and value from vested stock. Robert Stewart is not just an executive; he is shaping the future of affordable healthcare through innovative pharmaceutical solutions.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Amneal Pharmaceuticals, Inc. CEOs

A

Robert Stewart

Ex-CEO of Amneal Pharmaceuticals, Inc.

Education

Bachelor's degree in Pharmacy from the University of Southern California.

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of Amneal Pharmaceuticals, Inc. for

1 year 2 months (May 2018 - Aug 2019)

Previous Experience

Former President and Chief Executive Officer at Impax Laboratories, Inc.

Rivals

Competitors/colleagues of Robert Stewart

Holdings

See how much did Robert Stewart make over time.

As the CEO of Amneal Pharmaceuticals, Robert Stewart holds significant shares in the company, especially in Class A common stock (AMRX). Over the years, his ownership has mirrored the company's journey, witnessing fluctuations based on market conditions. At one point,...

As the CEO of Amneal Pharmaceuticals, Robert Stewart holds significant shares in the company, especially in Class A common stock (AMRX). Over the years, his ownership has mirrored the company's journey, witnessing fluctuations based on market conditions. At one point, his wealth was heavily tied to these holdings, reflecting his commitment to Amneal’s success. In 2019, Stewart’s stock holdings were worth around $300,000 after vesting 20,000 restricted stock units. Changes in the pharmaceutical sector can directly impact his holdings, making it crucial for him to stay aligned with the company’s growth and industry innovation. His wealth in stocks illustrates a deeper connection between his personal financial interests and the company's performance, emphasizing his role in steering Amneal forward.

Mar 17, 2025

A

shares

ACT @ $33.45

A

shares

AMRX @ $8.62

C

shares

CRMD @ $10.47

Insider Trading

See recent insider trades of Robert Stewart.

CRMD

$43.74K

CRMD at $4.37/share

May 17, 2023

Purchase

CRMD

$43.74K

CRMD at $4.37/share

May 17, 2023

Received

AMRX

$202.64K

AMRX at $11.92/share

Mar 12, 2019

Purchase

ACT

4,568 shares

ACT

Mar 5, 2015

Received

ACT

$666.62K

ACT at $197.05/share

May 9, 2014

Received

ACT

$1.33M

ACT at $166.02/share

Dec 9, 2013

Sale

ACT

$1.64M

ACT at $164.44/share

Nov 15, 2013

Sale

ACT

$1.90M

ACT at $158.39/share

Nov 11, 2013

Sale

ACT

71,252 shares

ACT

Oct 1, 2013

Received

ACT

44,312 shares

ACT

Sep 30, 2013

Received

Compensation History

See how much did Robert Stewart make over time.

In 2019, Robert Stewart received a total compensation of $950,000 as CEO of Amneal Pharmaceuticals. This amount included a fixed salary of $500,000, a performance-based bonus of $100,000, and $300,000 from vested restricted stock units. His bonus was awarded for meeting specific financial performance metrics, such as revenue growth and adjusted EBITDA targets. Stewart’s overall compensation reflects a mix of fixed and performance-based pay, designed to keep him aligned with the shareholders' interests. The company’s approach to compensation is all about accountability and results, recognizing Stewart's ability to lead the company effectively during a transformative period.

Year

2019

Total Compensation

$950.00K

Salary

$500.00K

Board Justification

The compensation philosophy aims to align CEO compensation with company performance and shareholder interests, using a mix of fixed and variable pay components.

Bonus

$100.00K

Board Justification

The bonus is based on the achievement of specific financial performance metrics set by the Board of Directors for the fiscal year 2019.

Other

$50.00K

Board Justification

Other compensation includes retirement contributions and health benefits provided to the CEO.

Restricted Stock

$300.00K(20K RSU)

Board Justification

The vested stock consists of restricted stock units (RSUs) that were granted in previous years and vested in 2019.

Performance Metrics

The performance metrics for 2019 included revenue growth and adjusted EBITDA targets.

Other Amneal Pharmaceuticals, Inc. CEOs

Here are other CEOs of Amneal Pharmaceuticals, Inc.

Chintu Patel

Founder and Ex-CEO of Amneal Pharmaceuticals, Inc.

August 2019 - March 2022